Chatelut E - Search Results

1

A phase I dose-escalating and pharmacokinetic study of docetaxel and vinorelbine as first-line chemotherapy for metastatic breast cancer.

Delord JP, Dalenc F, Pinguet F, Nguyen L, Lochon I, Poublanc M, Chatelut E, Roche H. Delord JP, et al. Among authors: chatelut e. Oncology. 2007;72(5-6):322-5. doi: 10.1159/000113055. Epub 2008 Jan 14. Oncology. 2007. PMID: 18187952 Clinical Trial.

2

Pharmacokinetic modeling of plasma and cerebrospinal fluid methotrexate after high-dose intravenous infusion in children.

Chatelut E, Roche H, Plusquellec Y, Peyrille F, De Biasi J, Pujol A, Canal P, Houin G. Chatelut E, et al. J Pharm Sci. 1991 Aug;80(8):730-4. doi: 10.1002/jps.2600800804. J Pharm Sci. 1991. PMID: 1791530

3

Teniposide and cisplatin given by intraperitoneal administration: preclinical and phase I/pharmacokinetic studies.

Chatelut E, de Forni M, Canal P, Chevreau C, Roche H, Plusquellec Y, Johnson NP, Houin G, Bugat R. Chatelut E, et al. Ann Oncol. 1991 Mar;2(3):217-21. doi: 10.1093/oxfordjournals.annonc.a057910. Ann Oncol. 1991. PMID: 2043492 Free article. Clinical Trial.

4

Pharmacokinetics and toxicity of two modalities of etoposide infusion in metastatic non-small-cell lung carcinoma.

Chatelut E, Chevreau C, Blancy E, Lequellec A, Canal P, Roche H, Houin G, Bugat R. Chatelut E, et al. Cancer Chemother Pharmacol. 1990;26(5):365-8. doi: 10.1007/BF02897295. Cancer Chemother Pharmacol. 1990. PMID: 2170043

5

Phase I/pharmacokinetic study of intraperitoneal teniposide (VM 26).

Canal P, Bugat R, Chatelut E, Pinel MC, Houin G, Plusquellec Y, Carton M. Canal P, et al. Among authors: chatelut e. Eur J Cancer Clin Oncol. 1989 May;25(5):815-20. doi: 10.1016/0277-5379(89)90126-0. Eur J Cancer Clin Oncol. 1989. PMID: 2737218

6

[Relations between hematological toxicity and total and free plasma levels of etoposide in daily oral administration].

Lavit M, Chevreau C, Chatelut E, De Fenin V, Lochon I, Houin G, Bugat R, Canal P. Lavit M, et al. Among authors: chatelut e. Bull Cancer. 1995 Aug;82(8):660-4. Bull Cancer. 1995. PMID: 7492822 French.

7

Prediction of carboplatin clearance from standard morphological and biological patient characteristics.

Chatelut E, Canal P, Brunner V, Chevreau C, Pujol A, Boneu A, Roché H, Houin G, Bugat R. Chatelut E, et al. J Natl Cancer Inst. 1995 Apr 19;87(8):573-80. doi: 10.1093/jnci/87.8.573. J Natl Cancer Inst. 1995. PMID: 7752255

8

Cerebrospinal fluid concentrations of carboplatin in a patient without blood-brain barrier disruption.

Brunner V, Houyau P, Chatelut E, Roché H, Canal P. Brunner V, et al. Among authors: chatelut e. Cancer Chemother Pharmacol. 1995;35(4):352-3. doi: 10.1007/BF00689459. Cancer Chemother Pharmacol. 1995. PMID: 7828282 No abstract available.

9

Escalating dose of mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in patients with refractory lymphoma undergoing autologous bone marrow transplantation.

Attal M, Canal P, Schlaifer D, Chatelut E, Dezeuze A, Huguet F, Payen C, Pris J, Laurent G. Attal M, et al. Among authors: chatelut e. J Clin Oncol. 1994 Jan;12(1):141-8. doi: 10.1200/JCO.1994.12.1.141. J Clin Oncol. 1994. PMID: 8270970 Clinical Trial.

10

[Prediction of carboplatin clearance from morphological and biological patient characteristics].

Chatelut E, Dezeuze A, Lavit M, Chevreau C, Pujol A, Boneu A, Roché H, Houin G, Bugat R, Canal P. Chatelut E, et al. Bull Cancer. 1995 Nov;82(11):946-53. Bull Cancer. 1995. PMID: 8535021 French.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

244 results

Search Page

Filters